Acute Renal Failure (ARF)/ Acute Kidney Injury – Pipeline Review, 2019

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content:

1. Introduction

1.1. ReportOverview

2. Acute Renal Failure (ARF)/ Acute Kidney Injury - Overview

3. Executive Summary

4. Acute Renal Failure (ARF)/ Acute Kidney Injury : Pipeline Assessment

4.1. By Stage ofDevelopment

4.2. By Route ofAdministration

4.3. By DrugClass

4.4. By MoleculeType

4.5. By TherapyArea / Indication

4.6. By DrugTarget

4.7. By Sponsor

5. Acute Renal Failure (ARF)/ Acute Kidney Injury: Company & DrugProfiles

5.1. ClinicalStage

5.1.1. QPI-1002– Quark Pharmaceuticals, Inc.

5.1.1.1. Company Overview

5.1.1.2. Product Description

5.1.1.3. R&D Status & Development Activities

5.1.1.4. Mechanism of Action

5.1.1.5. Molecule Type

5.1.1.6. Stage of Development

5.1.1.7. Indications

5.1.1.8. Route of Administration

5.1.1.9. Funding

5.1.2. CXA-10 – Complexa, Inc.

5.1.2.1. Company Overview

5.1.2.2. Product Description

5.1.2.3. R&D Status & Development Activities

5.1.2.4. Mechanism of Action

5.1.2.5. Molecule Type

5.1.2.6. Stage of Development

5.1.2.7. Indications

5.1.2.8. Route of Administration

5.1.2.9. Funding

5.1.3. CSL112  –CSL Behring 

5.1.3.1. Company Overview

5.1.3.2. Product Description

5.1.3.3. R&D Status & Development Activities

5.1.3.4. Mechanism of Action

5.1.3.5. Molecule Type

5.1.3.6. Stage of Development

5.1.3.7. Indications

5.1.3.8. Route of Administration

5.1.3.9. Funding

5.1.4. Others

5.2. Preclinical

5.2.1. Company Overview

5.2.2. Product Description

5.2.3. R&D Status & Development Activities

5.2.4. Mechanism of Action

5.2.5. Molecule Type

5.2.6. Indications

5.2.7. Route of Administration

5.2.8. Funding

6. Acute Renal Failure (ARF)/ Acute Kidney Injury: An Overview onDormant & Discontinued Pipeline Candidates

6.1. Overview

6.2. ProductDescription

6.3. Reason forDiscontinuation

7. Acute Renal Failure (ARF)/ Acute Kidney Injury: Additional KeyInsights

7.1.Epidemiology Overview: Acute Renal Failure (ARF)/ Acute Kidney Injury

7.2. Current Market Scenario: Acute Renal Failure(ARF)/ Acute Kidney Injury Therapeutics

8. Acute Renal Failure (ARF)/ Acute Kidney Injury: News, Press Releasesand Conference Details

Note:

1) This Table of Content is tentative and subject to change as the research progresses.

2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.